Congressional Republicans have expressed concerns towards the Food and Drug Administration (FDA) after the agency announced that it would not release the safety review of the abortion drug mifepristone until March. This comes after the FDA stated in a court filing that the study is expected to conclude by mid-December. A report outlining the findings is anticipated no later than March 2027, after which changes to the drug’s usage may be implemented.
Mifepristone, used in combination with misoprostol, is the leading method of abortion in the United States. Senator Josh Hawley from Missouri has questioned if the FDA is considering sufficient data on adverse events. In his letter, he pressed Acting FDA Commissioner Kyle Diamantas to verify whether the review includes data following the loosening of restrictions in 2023. This move aimed to expand availability through mail-order access.
In April 2021, the FDA announced the suspension of the in-person dispensing requirement for mifepristone during the COVID-19 public health emergency. In January 2023, they further modified the REMS (Risk Evaluation and Mitigation Strategy), allowing certified pharmacies to dispense the drug.
Representative Chip Roy from Texas issued a demand for the FDA to release the study immediately upon completion, rather than delaying until March. He requested transparency about reinstating the in-person dispensing requirement. Roy warned of proposing a bill amendment to bar funding from supporting regulations that permit mifepristone mailing and pharmacy dispensing. He stated, “House Republicans cannot be expected to continue funding the implementation of the January 2023 REMS modifications indefinitely while FDA repeatedly extends its review without committing to corrective action.”
Essential Reads: Healthcare Sector Impacts
Enrollment figures for ObamaCare and individual market health insurance plans have declined over the past year, according to analysis by KFF. Approximately 4.5 million people dropped coverage, marking an 18% reduction. This decrease coincides with the expiration of enhanced premium tax credits from COVID-era measures.
Additionally, Texas Attorney General Ken Paxton has filed a lawsuit against Gerber Products Co. and Nestlé USA, alleging dangerous levels of toxic metals in baby food. In response to a measles outbreak in 2026, Sen. Bill Cassidy criticized the Trump administration for insufficient promotion of vaccinations, emphasizing the importance of measles immunization to prevent widespread impact.
In Other News: Healthcare Developments
Senator Thom Tillis is questioning Elon Musk regarding Ukraine’s loss of military access to Starlink. California’s billionaire tax proposes healthcare relief, while its ramifications remain uncertain. Meanwhile, Idaho women are actively advocating for abortion rights in their communities.
